Literature DB >> 9203979

Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15.

T Yamabe1, K Takakura, K Sugie, Y Kitaoka, S Takeda, Y Okubo, K Teshigawara, J Yodoi, T Hori.   

Abstract

Activation of human natural killer (NK) cells involves sequential events including cytokine production and induction of cell surface molecules, resulting in the enhancement of cytolytic activity. To delineate the activation process of NK cells, we generated murine monoclonal antibodies (mAbs) against YT, a human large granular lymphocyte/natural killer (LGL/NK) cell line. Among the mAbs reactive with YT cells, one mAb, termed 2B9, was noted because of the lack of reactivity with most of the human T- and B-cell lines tested. In fresh peripheral blood mononuclear cells (PBMC), however, the majority of cells expressing this antigen (Ag) were T cells but not CD16+ nor CD56+ NK cells. Since YT cells showed an activated phenotype expressing interleukin-2 (IL-2) receptor alpha chain, we examined whether 2B9 Ag could be induced on normal human peripheral blood NK cells by cytokines known to activate NK cells. The 2B9 Ag was induced on NK cells by IL-2, IL-12 or IL-15 while no induction was observed by interferon-gamma (IFN-gamma). Biochemical analysis showed that anti-2B9 mAb recognized a 115 kDa molecule in YT cells. A cDNA clone encoding the 2B9 Ag was isolated from a cDNA expression library of YT cells and its sequence was identical to CD26 cDNA although it was not of full length. Transient expression of the 2B9 cDNA on COS-7 cells revealed that this cDNA encodes the antigenic epitope(s) recognized by anti-2B9 mAb as well as Ta1, an anti-CD26 mAb. These results showed that the 2B9 Ag is identical to CD26, and demonstrated that CD26 is an activation antigen on CD16+ CD56+ NK cells inducible by IL-2, IL-12 or IL-15.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203979      PMCID: PMC1364048          DOI: 10.1046/j.1365-2567.1997.00230.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

1.  Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways.

Authors:  N H Dang; Y Torimoto; K Deusch; S F Schlossman; C Morimoto
Journal:  J Immunol       Date:  1990-06-01       Impact factor: 5.422

2.  Peptidase activity of glycylprolyl beta-naphthylamidase from human submaxillary gland.

Authors:  H Oya; M Harada; T Nagatsu
Journal:  Arch Oral Biol       Date:  1974-06       Impact factor: 2.633

3.  Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity.

Authors:  W G Gutheil; M Subramanyam; G R Flentke; D G Sanford; E Munoz; B T Huber; W W Bachovchin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

4.  Cytokine-enhanced NK cell-mediated cytotoxicity. Positive modulatory effects of IL-2 and IL-12 on stimulus-dependent granule exocytosis.

Authors:  J D Bonnema; K A Rivlin; A T Ting; R A Schoon; R T Abraham; P J Leibson
Journal:  J Immunol       Date:  1994-03-01       Impact factor: 5.422

5.  Direct association of adenosine deaminase with a T cell activation antigen, CD26.

Authors:  J Kameoka; T Tanaka; Y Nojima; S F Schlossman; C Morimoto
Journal:  Science       Date:  1993-07-23       Impact factor: 47.728

6.  Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor.

Authors:  K H Grabstein; J Eisenman; K Shanebeck; C Rauch; S Srinivasan; V Fung; C Beers; J Richardson; M A Schoenborn; M Ahdieh
Journal:  Science       Date:  1994-05-13       Impact factor: 47.728

7.  Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness.

Authors:  M Subramanyam; W G Gutheil; W W Bachovchin; B T Huber
Journal:  J Immunol       Date:  1993-03-15       Impact factor: 5.422

8.  Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS.

Authors:  B G Brenner; M Gornitsky; M A Wainberg
Journal:  Clin Diagn Lab Immunol       Date:  1994-09

9.  Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells.

Authors:  F Bühling; D Kunz; D Reinhold; A J Ulmer; M Ernst; H D Flad; S Ansorge
Journal:  Nat Immun       Date:  1994 Sep-Oct

10.  Detection of adult T-cell leukemia-derived factor/human thioredoxin in human serum.

Authors:  Y Kitaoka; K Sorachi; H Nakamura; H Masutani; A Mitsui; F Kobayashi; T Mori; J Yodoi
Journal:  Immunol Lett       Date:  1994-07       Impact factor: 3.685

View more
  13 in total

Review 1.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

Review 2.  Dipeptidyl peptidase-4: a key player in chronic liver disease.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

3.  Matrix metalloproteinases in cytotoxic lymphocytes impact on tumour infiltration and immunomodulation.

Authors:  Karin Edsparr; Per H Basse; Ronald H Goldfarb; Per Albertsson
Journal:  Cancer Microenviron       Date:  2010-11-27

Review 4.  Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?

Authors:  Aleksi Sedo; Jonathan S Duke-Cohan; Eva Balaziova; Liliana R Sedova
Journal:  Arthritis Res Ther       Date:  2005-10-26       Impact factor: 5.156

Review 5.  Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure.

Authors:  Thiago A Salles; Leonardo dos Santos; Valério G Barauna; Adriana C C Girardi
Journal:  Int J Mol Sci       Date:  2015-02-16       Impact factor: 5.923

Review 6.  Ectopeptidases in pathophysiology.

Authors:  C Antczak; I De Meester; B Bauvois
Journal:  Bioessays       Date:  2001-03       Impact factor: 4.345

Review 7.  Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function.

Authors:  Quan Gong; Sanjay Rajagopalan; Jixin Zhong
Journal:  Int J Cardiol       Date:  2015-06-27       Impact factor: 4.164

8.  Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction.

Authors:  Grazia Esposito; Donato Cappetta; Rosa Russo; Alessia Rivellino; Loreta Pia Ciuffreda; Fiorentina Roviezzo; Elena Piegari; Liberato Berrino; Francesco Rossi; Antonella De Angelis; Konrad Urbanek
Journal:  Br J Pharmacol       Date:  2017-03-21       Impact factor: 8.739

9.  Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome.

Authors:  Valérie Turcot; André Tchernof; Yves Deshaies; Louis Pérusse; Alexandre Bélisle; Picard Marceau; Frédéric-Simon Hould; Stéfane Lebel; Marie-Claude Vohl
Journal:  Diabetol Metab Syndr       Date:  2013-02-04       Impact factor: 3.320

10.  Sodium butyrate has context-dependent actions on dipeptidyl peptidase-4 and other metabolic parameters.

Authors:  Eun-Sol Lee; Dong-Sung Lee; Prakash Raj Pandeya; Youn-Chul Kim; Dae-Gil Kang; Ho-Sub Lee; Byung-Chul Oh; Dae Ho Lee
Journal:  Korean J Physiol Pharmacol       Date:  2017-08-22       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.